The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: A randomized, double-blind, parallel-group, flexible-dose study

International Clinical Psychopharmacology

Volumn 27, Issue 6, 2012, Pages 326-335

  Kwon, Jun Soo ^a,b   Mittoux, Aurélia ^d   Hwang, Jae Yeon ^a,c   Ong, Adeline ^d   Cai, Zhuo Ji ^e   Su, Tung Ping ^f  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

^d H LUNDBECK A S   (Denmark)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

olanzapine; safety; schizophrenia; sertindole; treatment outcome

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; HALOPERIDOL; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; ZOTEPINE;

ADULT; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPERSOMNIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; BENZODIAZEPINES; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MIDDLE AGED; SCHIZOPHRENIA; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866991635     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32835767a0     Document Type: Article

References (40)

1. Ahmad K, Dorian P (2007). Drug-induced QT prolongation and proarrhythmia: an inevitable link? Europace 9 (Suppl 4):iv16-iv22.
2. AstraZeneca (2011a). Seroquel (quetiapine fumarat) tablets/US prescribing information. Available at: http://www1.astrazeneca-us.com/pi/Seroquel.pdf. [Accessed 4 April 2012].
3. AstraZeneca (2011b). Seroquel XR (quetiapine fumarat) extended-release tablets/US prescribing information. Available at: http://www1.astrazenecaus. com/pi/seroquelxr.pdf. [Accessed 4 April 2012].
4. Azorin JM, Strub N, Loft H (2006). A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol 21:49-56. (Pubitemid 43175123)
5. Azorin JM, Murteira S, Hansen K, Toumi M (2008). Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis. BMC Psychiatry 8:16.
6. Azorin JM, Kaladjian A, Fakra E, Adida M (2010). Sertindole for the treatment of schizophrenia. Expert Opin Pharmacother 11:3053-3064.
7. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676. (Pubitemid 19154942)
8. Boidi G, Ferro M (2007). Rapid dose initiation of quetiapine for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel-group, open study. Hum Psychopharmacol 22:299-306. (Pubitemid 47180391)
9. Crocq MA, Naber D, Lader MH, Thibaut F, Drici M, Everitt B, et al. (2010). Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. Eur Neuropsychopharmacol 20:829-838.
10. De Hert M, Mittoux A, He Y, Peuskens J (2011). Metabolic parameters in the short-and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci 261:231-239.
11. Gallhofer B, Jaanson P, Mittoux A, Tanghoj P, Lis S, Krieger S (2007). Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 40:275-286. (Pubitemid 350232820)
12. Guy W (1976a). Clinical Global Impressions (CGI). In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs. pp. 218-222.
13. Guy W (1976b). Abnormal Involuntary Movement Scale (AIMS). In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs. pp. 534-537.
14. Hale AS (1998). A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol 13 (Suppl 3):S65-S70. (Pubitemid 28282873)
15. Hale A, Azorin J-M, Kasper S, Maier W, Syvalahti E, Van Der Burght M, et al. (2000). Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psychiatry Clin Pract 4:55-62. (Pubitemid 30198337)
16. Haverkamp W, Eckardt L, Matz J, Frederiksen K (2002). Sertindole: cardiac electrophysiological profile. Int J Psychiatry Clin Pract 6:11-20.
17. Hyttel J, Nielsen JB, Nowak G (1992). The acute effect of sertindole on brain 5-HT2, D2 and alpha 1 receptors (ex vivo radioreceptor binding studies). J Neural Transm Gen Sect 89:61-69.
18. Indik JH, Pearson EC, Fried K, Woosley RL (2006). Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 3:1003-1007. (Pubitemid 44283697)
19. Kasper S, Hale A, Azorin J-M, Mü ller H-J (1999). Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 249:S1-S14.
20. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276. (Pubitemid 18039085)
21. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, et al. (2010). Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: CD006654.
22. Lançon C, Toumi M, Sapin C, Hansen K (2008). The Sertindole safety survey: a retrospective analysis under a named patient use programme in Europe. BMC Psychiatry 8:57.
23. Lindstrom E, Farde L, Eberhard J, Haverkamp W (2005). QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol 8:615-629. (Pubitemid 41400893)
24. Monteleone P, Martiadis V, Maj M (2009). Management of schizophrenia with obesity, metabolic, and endocrinological disorders. Psychiatr Clin North Am 32:775-794.
25. Moore N (2002). Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int J Psychiatry Clin Pract 6:3-9.
26. Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B (2003). Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 12:271-281. (Pubitemid 36700601)
27. Murdoch D, Keating GM (2006). Sertindole: a review of its use in schizophrenia. CNS Drugs 20:233-255.
28. Pae CU, Kim JJ, Lee CU, Lee SJ, Lee C, Patkar AA, et al. (2007). Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial. J Clin Psychiatry 68:399-405. (Pubitemid 46506804)
29. Pezawas L, Quiner S, Moertl D, Tauscher J, Barnas C, Kufferle B, et al. (2000). Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance. Int Clin Psychopharmacol 15:207-214. (Pubitemid 30433521)
30. Piotrovsky V (2005). Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 7:E609-E624.
31. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
32. Skarsfeldt T (1992). Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 10:25-33.
33. Smith MA, McCoy R, Hamer-Maansson J, Brecher M (2005). Rapid dose escalation with quetiapine: a pilot study. J Clin Psychopharmacol 25: 331-335. (Pubitemid 41060252)
34. Suzuki T, Remington G, Mulsant BH, Rajji TK, Uchida H, Graff-Guerrero A, Mamo DC (2011). Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr Res 133:54-62.
35. Thomas SH, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, et al. (2010). Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 122:345-355.
36. Van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB (1996). A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 124:168-175. (Pubitemid 26112786)
37. Wehnert A (1998). The European Post-marketing Observational Serdolect (EPOS) Project: increasing our understanding of schizophrenia therapy. Int Clin Psychopharmacol 13 (Suppl 3):S27-S30. (Pubitemid 28282867)
38. Wilton LV, Heeley EL, Pickering RM, Shakir SA (2001). Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 15:120-126. (Pubitemid 32619589)
39. Wirshing DA,Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. (1999). Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60:358-363. (Pubitemid 29289721)
40. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. (1997). Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 154:782-791. (Pubitemid 27230100)